Friday, 20 November 2026European Markets

POXEL Stock Bullish Momentum With A 19% Rise In The Last 5 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - shares of poxel (cac 40: poxel.pa) jumped by a staggering 19.01% in 5 sessions from €0.69 to €0.82 at 16:09 est on thursday, following the last session's downward trend. cac 40 is falling 0.2% to €7,310.38, after two consecutive sessions in a row of losses.

poxel's last close was €0.86, 73.89% below its 52-week high of €3.28.

about poxel

poxel s.a., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. the company's lead product is twymeeg (imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in japan. it also develops pxl770, an adenosine monophosphate-activated protein kinase enzyme, which is in a phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (nash). poxel s.a. has a licensing agreement with enyo pharma s.a.s. for the development of farnesoid x receptor that is in phase 2a study for the treatment of hepatitis b and nash; and deuterx llc for the development of pxl065, a mitochondrial pyruvate carrier inhibitor, which is in a phase i clinical trial for the treatment of nash. the company was incorporated in 2009 and is headquartered in lyon, france.

earnings per share

as for profitability, poxel has a trailing twelve months eps of €-1.25.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -323.36%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, poxel's stock is considered to be oversold (<=20).

more news about poxel (poxel.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 9 Mar 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›